Physician profile
Randy K Mclaughlin
NPI 1205892312
$1,914.93
in general payments reported to CMS, 2019-2025
24 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $331 · 2021: $177 · 2022: $129 · 2023: $191 · 2024: $351 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $277.78 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $266.28 | 2019-2025 | Ozempic, Rybelsus |
| Inogen, INC. | $146.34 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Glaxosmithkline, LLC. | $133.19 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $127.56 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $125.75 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $95.78 | 2019-2023 | Camzyos |
| Amarin Pharma, INC. | $94.30 | 2019-2021 | |
| Esperion Therapeutics, INC. | $88.70 | 2020-2021 | |
| Lilly USA, LLC | $88.63 | 2020-2025 | Mounjaro, Zepbound |
| Amgen INC. | $88.12 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.26 | 2020-2021 | |
| Exact Sciences Corporation | $42.91 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $40.21 | 2019-2020 | |
| Abbvie INC. | $33.10 | 2021-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $29.45 | 2024 | Rexulti |
| Philips North America LLC | $28.90 | 2024 | (Ck7) Extended Holter |
| Circassia INC. | $28.53 | 2019 | |
| Eisai INC. | $24.06 | 2024 | |
| Xeris Pharmaceuticals, INC. | $24.01 | 2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $18.47 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $18.14 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.93 | 2021 | |
| Dexcom, INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.